GOODWILL AND INTANGIBLE ASSETS

6 Months Ended

Mar. 30, 2018

Goodwill and Intangible Assets Disclosure [Abstract]

The following table reflects the activity of goodwill by reportable operating segment:



(In millions)	Oncology Systems		Varian Particle Therapy		Total
Balance at September 29, 2017	$	170.2	$	52.4	$	222.6
Business combinations	11.5		—		11.5
Foreign currency translation adjustments	—		2.1		2.1
Balance at March 30, 2018	$	181.7	$	54.5	$	236.2

See Note 3, "Business Combinations" for more information on the Company's acquisitions in fiscal year 2018.

The following table reflects the gross carrying amount and accumulated amortization of the Company's intangible assets:



	March 30, 2018							September 29, 2017
(In millions)	Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount		Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount
Technologies and patents	$	118.0	$	(67.7	)	$	50.3	$	102.0	$	(60.9	)	$	41.1
Customer contracts and supplier relationship	38.2		(16.4		)	21.8		33.9		(14.3		)	19.6
Other	5.7		(4.6		)	1.1		5.5		(3.4		)	2.1
Total intangible with finite lives	161.9		(88.7		)	73.2		141.4		(78.6		)	62.8
In-process research and development with indefinite lives	8.8		—			8.8		8.8		—			8.8
Total intangible assets	$	170.7	$	(88.7	)	$	82.0	$	150.2	$	(78.6	)	$	71.6

Amortization expense for intangible assets was $4.1 million and $3.5 million during the three months ended March 30, 2018 and March 31, 2017, respectively, and $10.4 million and $7.3 million during the six months ended March 30, 2018 and March 31, 2017, respectively.

As of March 30, 2018, the Company estimates its remaining amortization expense for intangible assets with finite lives will be as follows (in millions):



Fiscal Years:	Remaining Amortization Expense
Remainder of 2018	$	10.9
2019	15.2
2020	12.7
2021	10.4
2022	9.0
Thereafter	15.0
Total remaining amortization for intangible assets	$	73.2

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details